Iovance Biotherapeutics, Inc. IOVA
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the immune system's natural ability to recognize and attack cancer cells …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees975
TickerIOVA
Statistics
Market Cap$1.72B
Revenue (TTM)$263.5M
Net Income-$391.0M
Net Margin-148.4%
EPS$-0.92
P/E-3.64
P/S6.19
P/B2.40
EV/EBITDA-4.42
ROE-47.5%
Dividend Yield—
Price$3.94
Data: Twelve Data · Revenue = mcap / P/S